Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Antidrug antibodies against CPIs

Benjamin Besse • 31 Jan 2020
BTOG 2020
Lung Cancer Antibodies Checkpoint Inhibitors

Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, outlines a paper he recently co-authored on the formation of antidrug antibodies (ADAs) against immune checkpoint blockers. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Benjamin Besse

2:38
AZD7789 in NSCLC: safety, efficacy, and ongoing evaluation
Benjamin Besse • 24 Oct 2023
1:47
Combining ADCs with other treatment modalities in NSCLC
Benjamin Besse • 24 Oct 2023
2:50
ADC’s for the treatment of NSCLC
Benjamin Besse • 24 Oct 2023
2:28
Optimal duration of immunotherapy administration for patients with NSCLC
Benjamin Besse • 21 Oct 2023

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals